News >

Strosberg Discusses Lutathera Approval, Remaining Challenges in NETs

Caroline Seymour
Published: Wednesday, Feb 28, 2018

Jonathan Strosberg, MD

Jonathan Strosberg, MD
Findings from the phase III NETTER-1 trial led to the January 2018 FDA approval of Lutathera (lutetium Lu 177 dotatate) for the treatment of patients with somatostatin receptor–positive gastroenteropancreatic tumors (GEP-NETs). The trial compared Lutathera with high-dose octreotide LAR for patients with 1 or 2 metastatic midgut NETs.

 on Gastrointestinal Cancers, Jonathan R. Strosberg, MD, an associate professor of Moffitt Cancer Center, discussed ongoing advances and challenges in the treatment of patients with NETs.

OncLive: How has treatment for patients with NETs and carcinoid syndrome evolved over the past couple years?

Strosberg: It has been a pretty exciting couple of years in the treatment of NETs and carcinoid syndrome. We've had the approval of everolimus (Afinitor) a few years ago for the treatment of progressive NETs of the gastrointestinal (GI) tract and lungs. Last year, we saw the approval of telotristat ethyl (Xermelo), a serotonin inhibitor, for the treatment of diarrhea related to carcinoid syndrome. [Recently] Lutathera, a radiolabeled somatostatin analog, was approved for the treatment of patients with progressive GEP-NETs. 

Can you explain the significance of the Lutathera approval?

Radiolabeled somatostatin analogs have been developed for the past several decades, primarily in Europe. They have been manufactured in hospitals and have treated thousands of patients. The principle is delivery of a radioactive somatostatin analog to a somatostatin receptor–expressing NET.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication